clinical trial · NCT07730489
A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
Sichuan Baili Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 130
Colorectal CancerBL-M07D1RegorafenibFruquintinibTAS-102
brief summary
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with advanced colorectal cancer who have HER2 IHC3+ and have failed prior treatment with oxaliplatin, fluorouracil and irinotecan.
started
Aug 1, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Aug 27, 2026
official title
A Phase III Randomized Controlled Clinical Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol